The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term survival (S) of induction chemotherapy (CTx) with three cycles cisplatin (cis)/paclitaxel (pac) followed by concurrent (cc) chemoradiation (CTx/RTx) cis/etoposide (eto) and 45 Gy (1.5 Gy bid) plus surgery (SURG): Phase II results (CISTAXOL).
W. E. E. Eberhardt
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
T. C. Gauler
No relevant relationships to disclose
C. Le Pechoux
No relevant relationships to disclose
R. Hepp
No relevant relationships to disclose
S. Welter
No relevant relationships to disclose
B. Fischer
Research Funding - Bristol-Myers Squibb
S. Bildat
No relevant relationships to disclose
D. Grunenwald
No relevant relationships to disclose
G. Stamatis
No relevant relationships to disclose
M. Stuschke
No relevant relationships to disclose
C. Poettgen
No relevant relationships to disclose